

Freedom of Information Request: Our Reference CTMUHB_08_26

You asked:

Under the Freedom of Information Act of 2000, I would like to request the following information for your healthcare trust during the period 1st Jan 2015 to 31st December 2025:

1. Annual number of patients diagnosed with blood cancers per year overall, and by subtype:

- **Lymphomas (C81-86)**
 - **Malignant immunoproliferative diseases (C88)**
 - **Multiple myeloma and malignant plasma cell neoplasms (C90)**
 - **Leukaemia (C91-C95)**
 - **Unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues (C96)**
-
- Lymphomas (C81-86) - 63
 - Malignant immunoproliferative diseases (C88) - *Less than 5
 - Multiple myeloma and malignant plasma cell neoplasms (C90) - 23
 - Leukaemia (C91-C95) - 33
 - Unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues (C96) - 0

*Where the figures are less than 5, the exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

2. The number of blood cancer clinical trials available, including active trials that are recruiting and trials that are not actively recruiting.

No interventional clinical trials relating to blood cancer have been open to recruitment at CTMUHB during this time period.

The number of observational studies open in CTMUHB relating to blood cancer is as follows:

[illegible]

3. Annual number of patients who were enrolled in interventional or observational clinical trials related to these blood cancers per year.

No patients have been enrolled in interventional clinical trials or observational studies at CTMUHB during this time period.

4. The scientific title, clinical trial registration number, phase (I/II/III/IV/other), opening and closing recruitment dates, number recruited at this trust, and location of each trial related to blood cancer.

No interventional clinical trials relating to blood cancer have been open to recruitment at CTMUHB during this time period.

The observational research studies relating to blood cancers are as follows:

Scientific Title	Clinical Trial Registration Number	Phase	Open	Closed	Patients	Location
A prospective long-term observational study in patients with monoclonal gammopathy of undetermined significance	NCT05539079	N/A	02/01/2026	N/A	0	Prince Charles Hospital & The Royal Glamorgan Hospital
Diagnostic Journeys in Myeloma (DJiM): how long does it take to be diagnosed?	Unavailable	N/A	01/08/2014	29/02/2016	*Less than 5	Prince Charles Hospital & The Royal Glamorgan Hospital

5. The current number of dedicated research staff (e.g. research nurses, research practitioners, study coordinators etc.) assigned to haematological clinical trials.

There is no specific number of CTMUHB's R&D Delivery staff allocated to haematological clinical trials as allocation is undertaken on a study-by-study basis, dependent on support required.

6. If available, annual counts of invitations/offers made to eligible patients to consider trial participation.

Information not held. CTM patients may also be referred to specialist centres for treatment and offered clinical trial participation at that centre.